re: AUPH - Aurinia Pharmaceuticals

quote:

---

How did you start your search and come up with those tickers like that?

---

BCRX is unavoidable if you've followed the AUPH StockTwits for any length of time.
It's constantly being compared for dumb reasons: Similar prices, similar market caps, similar drug launch dates, etc.

----------

I wanted to buy around $10 but waited too long. They are doing really well with their new drug just two quarters into its launch. Not as much peak sales potential as Lupkynis (300-400 million vs 1B+), but BCRX has a much larger pipeline.

----------

I posted some [link=(AKBA research)]https://www.tigerdroppings.com/rant/money/akebia-therapeutics-akba--possibly-my-next-long-position/94902708/[/link] months ago, and it is very much in accumulation price range with no changes in data. It's a buy. I've accumulated 333 shares and this is one that I could see myself owning 2-3k shares of (much like AUPH). Possibly more if shares stay sub $5.

-----------

CARA is one that I've followed off and on for as long as I've followed AUPH. For me, it's not as cut and dry as AUPH with numerous drugs, and it's a bit harder for me to understand the science behind their stuff. That's just me, maybe someone can shed light on them.

-----------

I ran across CFMS just last night. I think I saw it on StockTwits. To me, this just seems like a good company with solid growth, but with room for much more.
Current market cap of 280 million and $1.50/share. From their website: "Conformis enables personalized knee and hip joint replacement procedures. We are the only company that designs and manufactures truly personalized joint replacements for your unique anatomy." They hope to take market share away from Stryker (103B dollar company).

The company is profitable:

quote:

---

ConforMIS (CFMS) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.03 per share a year ago.

This quarterly report represents an earnings surprise of 162.50%. A quarter ago, it was expected that this medical technology company would post a loss of $0.08 per share when it actually produced a loss of $0.09, delivering a surprise of -12.50%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

---

I'd like to start a position in CFMS very soon.

Have you been looking at HEPA? They might be in a similar place to AUPH in January 2017. With the advantage of a product aiming at a lot more people. NASH is a disease (or perhaps a syndrome) associated with obesity. That's an emerging worldwide problem. There are no drugs at present capable of stopping the scarring/fibrosis component of NASH and the preliminary results are promising

quote:

---

NASH is a disease (or perhaps a syndrome) associated with obesity. That's an emerging worldwide problem. There are no drugs at present capable of stopping the scarring/fibrosis component of NASH and the preliminary results are promising

---

Has ANYONE made it past phase 2 NASH trials? I've struck out at least twice on stocks that supposedly had NASH in the bag until they didn't

RSI cooling off. We'll be ready for $18+ soon enough.

Motley Fool 16 August: Ready to buy!

If Motley Fool investors are going to start small with any company, I would recommend growth stock Aurinia Pharmaceuticals (TSX:AUP)(NASDAQ:AUPH). This pharmaceutical company basically shut down during the pandemic. Revenue plummeted as the company saw its funds taken away to help fund the pandemic.

This sounds like a bad situation, and it was. But that’s behind the company now. Aurinia is now a top stock for those seeking to retire early. That’s because of its recent oral therapy drug, LUPKYNIS. This is the first FDA-approved oral therapy drug for lupus nephritis. Analysts are incredibly excited, especially after the company recently reported its future outlook. The drug is set to go global, with management expecting top-line results.

On the outside, it can look bad. The company continues to increase losses, which management chalks up to the launch of LUPKYNSIS. So that means it’s at least short-term losses. The company, however, expects annual revenue to reach close to $50 million in 2021, with enough to fund through 2023. By 2022, sales should increase by an incredible 352%!

Foolish takeaway
Yet today, shares continue to trade at just under $17 per share, down 9.7% in the last year. Meanwhile, analysts believe the company will see an average potential upside in shares of 119% in the next year! This is the perfect growth stock for those looking to retire early.

Aurinia is a company that should explode, creating even more opportunities after two years of hardship. And with shares up 16.7% in the last month alone, it’s a great time to ride the wave.

Does that mean that you need to see $20.69 to break even?

Oh I see, you probably just need a couple of nice days to sell your contracts for more than what you paid for them. Is that the play?

quote:

---

Does that mean that you need to see $20.69 to break even?

Oh I see, you probably just need a couple of nice days to sell your contracts for more than what you paid for them. Is that the play?

---

Correct on both. I was hoping for a BO but I don't want to get caught at the end of the year if we are still trading around $15-17. I bought these last year.

quote:

---

Out till January id get the hell out. I've been shopping like 30 or 40 calls that far out.

---

That is what I am thinking. I will roll it into shares and say F it. I had my chance the other day but I got greedy.

I want to hold the options until end of q3 but I am getting nervous.

Basically yes. I am worried that the recent buying will stop and we float back to around the $14-15 range.

I hope you are right. I bought these things last year thinking that it was plenty of time foe the BO.